Acute lymphoblastic leukemia of T progenitors: from biology to clinics

Eulàlia Genescà, Jordi Ribera, Josep Maria Ribera

Research output: Contribution to journalReview articleResearchpeer-review

3 Citations (Scopus)


Copyright © 2013 Elsevier España, S.L.U. All rights reserved. Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the main cause of morbidity among childhood blood disorders. There are 2 subtypes according to the affected lymphoid progenitor: B-ALL and T-ALL. The T-ALL is the less common and, although historically was associated with poor prognosis in both adults and children, at present, treatment outcomes do not differ significantly between the 2 types of ALL. The T-ALL subtype is the most complex and heterogeneous at the genetic level and currently the one with less new therapeutic alternatives available. This trend is changing thanks to the remarkable progress upon understanding its biology. This review summarizes the most recent and important biological findings in T-ALL and their possible therapeutic implications.
Original languageEnglish
Pages (from-to)223-229
JournalMedicina clínica
Issue number5
Publication statusPublished - 9 Mar 2015


  • Acute T-cell lymphoblastic leukemia
  • Biology
  • Biología
  • Leucemia aguda linfoblástica T
  • Marcadores moleculares
  • Molecular markers
  • Tratamiento
  • Treatment


Dive into the research topics of 'Acute lymphoblastic leukemia of T progenitors: from biology to clinics'. Together they form a unique fingerprint.

Cite this